<DOC>
	<DOCNO>NCT00123916</DOCNO>
	<brief_summary>Evaluate benznidazole , antiparasite drug , give dose calculate 5mg/kg/day 60 day , administer fix daily dose 300mg 40 80 day treatment - period adjust accord patient 's body weight total minimum dose 12g ( correspond 40kg ) total maximum dose 24g ( correspond 80kg ) - reduces morbidity mortality patient Chronic Chagas ' Cardiomyopathy ( CCC ) . The BENEFIT study conduct Population Health Research Institute ( Hamilton , Canada ) Institute Dante Pazzanese de Cardiologia ( Sao Paulo , Brazil ) together independent Steering Committee .</brief_summary>
	<brief_title>BENEFIT : Evaluation Use Antiparasital Drug ( Benznidazole ) Treatment Chronic Chagas ' Disease</brief_title>
	<detailed_description>A randomized double-blind control clinical trial investigate role benznidazole patient chronic Chagas ' heart disease . Chagas disease 3 phase : acute , undetermined chronic phase . There clinical trial date investigate use antiparasitic drug patient chronic phase . This study evaluate efficacy safety benznidazole ( antiparasitic drug ) patient chronic Chagas ' heart disease . Evaluate benznidazole , antiparasite drug , give dose calculate 5mg/kg/day 60 day , administer fix daily dose 300mg 40 80 day treatment - period adjust accord patient 's body weight total minimum dose 12g ( correspond 40kg ) total maximum dose 24g ( correspond 80kg ) - reduces morbidity mortality patient Chronic Chagas ' Cardiomyopathy ( CCC ) . It develop 54 study centre Argentina , Bolivia , Brazil , Colombia El Salvador - country high incidence Chagas Disease . The Pilot study evaluate benznidazole effective produce parasitic cure ( PCR negativization reduce parasitic load ) chronic Chagas Disease well assess feasibility conduct large trial chronic Chagas Disease South America .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Benzonidazole</mesh_term>
	<criteria>Consenting patient ( 18 75 year age ) serological evidence Chagas infection ( combination 2 positive test ) one following : Abnormal electrocardiogram least two component ( complete RBBB LBBB ; leave anterior posterior fascicular block ; ventricular premature beat ; first degree atrioventricular [ AV ] block ; Mobitz type I AV block ; sinus bradycardia ; primary STT change ; abnormal Q wave ; low voltage QRS ; atrial fibrillation ) ; Abnormal ECG ( Mobitz type II , advance third degree AV block ) ; Increased cardiothoracic ratio ( &gt; 0.50 ) ; Complex ventricular arrythmias 24 hour ambulatory ECG monitoring ; Evidence regional wall motion abnormality reduce global leave ventricular systolic function increase leave ventricular diastolic diameter 2DEcho . Patients exclude : NYHA heart failure class IV decompensated heart failure Evidence concomitant coronary artery disease ( CAD ) etiology dilate cardiomyopathy Previous treatment antitrypanosomal agent accept indication antiparasitic therapy Inability comply followup visit History severe alcohol abuse within 2 year Known chronic renal hepatic insufficiency hepatic insufficiency Pregnancy breast feed Megaesophagus swallow impairment Other severe disease significantly curtail life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Chagas Disease</keyword>
	<keyword>Trypanosomiasis</keyword>
	<keyword>Benznidazole</keyword>
	<keyword>Chronic Heart disease</keyword>
	<keyword>Trypanosoma Cruzi</keyword>
</DOC>